Brain Research, 73 (1996) 375–378
© 1996 Elsevier Science B.V.

Author Index

Ahmed, S., see Lewy, A.J., 131
Amara, D.A., see Ramboz, S., 305
Ashby Jr., C.R., see Wang, R.Y., 7
Auerbach, S.B., see Hjorth, S., 281
Aulakh, C., see Murphy, D.L., 209
Austin, R.H., see Sleight, A.J., 245
Azmitia, E.C., see Patel, T.D., 319
Azzaro, A.J., see Johnson, E.A., 331

Bagdy, G.
Role of the hypothalamic paraventricular nucleus in 5-HT_{1A}, 5-HT_{2A} and 5-HT_{2C} receptor-mediated oxytocin, prolactin and ACTH/corticosterone responses, 277
Baxter, G.S.
Novel discriminatory ligands for 5-HT_{2B} receptors, 149
Beattie, D.T., see Skingle, M., 157
Becker, H., see Hennig, J., 359
Belzung, C., see Ramboz, S., 305
Benloucif, S., see Dubocovich, M.L., 141
Bervoets, K., see Millan, M.J., 69
Bill, D.J., see Fletcher, A., 337
Bockaert, J., see Waeber, C., 259
Bonhaus, D.W., see Wong, E.H.F., 249
Bonson, K.R. and Murphy, D.L.
Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium, 299
Borroni, E., see Sleight, A.J., 245
Bourson, A., see Sleight, A.J., 245
Bradberry, C.W., see Cunningham, K.A., 93
Briggs, N.C., see Murphy, D.L., 209
Brown, D.R.
Mucosal protection through active intestinal secretion: neural and paracrine modulation by 5-hydroxytryptamine, 193
Brown, G., see Fletcher, A., 337
Buhot, M-C., see Ramboz, S., 305
Burnet, P.W.J., Mefford, I.N., Smith, C.C., Gold, P.W. and Sternberg, E.M.
Hippocampal 5-HT_{1A} receptor binding site densities, 5-HT_{1A} receptor messenger ribonucleic acid abundance and serotonin levels parallel the activity of the hypothalamo-pituitary-adrenal axis in rats, 365
Burton, M., see Price, G.W., 79

Callebert, J., see Choi, D-S., 253
Chang, A.S., see Cunningham, K.A., 93
Chang, L., see Grob, C.S., 103
Chen, K., see Shih, J.C., 59
Childs, K.J., see Fletcher, A., 337
Choi, D-S., Loric, S., Colas, J-F., Callebert, J., Rosay, P., Kellermann, O., Launay, J-M. and Maroteaux, L.
The mouse 5-HT_{2B} receptor: homologous subtype or species variant?, 253
Čičin-Šain, L. and Jernej, B.
Reduction of gastrointestinal serotonin in alloxan-diabetic rats: reversal by 5-hydroxytryptophan treatment, 285
Clancy Jr., J., see Mathews, H.L., 369
Clancy Jr., J. and Lorens, S.
Subchronic and chronic exposure to *d*-fenfluramine dose-dependently enhances splenic immune functions in young and old male Fischer-344 rats, 355
Clement, M.E., see McCall, R.B., 297
Cliffe, I.A., see Fletcher, A., 337
Cohen, M.L., see Cox, D.A., 289
Colas, J-F., see Choi, D-S., 253
Connor, H.E., see Skingle, M., 157
Copolov, D.L., see Dean, B., 169
Corradetti, R., see Fletcher, A., 337
Cortés, R., see Palacios, J.M., 239
Cox, D.A. and Cohen, M.L.
5-HT_{2B} receptor signaling in the rat stomach fundus: dependence on calcium influx, calcium release and protein kinase C, 289
Critchley, D.J.P., see Fletcher, A., 337
Cunningham, K.A., Bradberry, C.W., Chang, A.S. and Reith, M.E.A.
The role of serotonin in the actions of psychostimulants: molecular and pharmacological analyses, 93

Dannals, R.F., see Szabo, Z., 221
Dean, B., Hayes, W., Opeskin, K., Naylor, L., Pavey, G., Hill, C., Keks, N. and Copolov, D.L.
Serotonin$_2$ receptors and the serotonin transporter in the schizophrenic brain, 169
Detke, M.J. and Lucki, I.
Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test: the effects of water depth, 43
Dourish, C.T., see Fletcher, A., 337
Druse, M., see Whitaker-Azmitia, P.M., 19
Dubocovich, M.L., Benloucif, S. and Masana, M.I.
Melatonin receptors in the mammalian suprachiasmatic nucleus, 141
Dumuis, A., see Waeber, C., 259

Edwards, R.H., see Liu, Y., 51
Eglen, R.M., see Wong, E.H.F., 249
Eison, A.S. and Mullins, U.L.
Regulation of central 5-HT_{2A} receptors: a review of in vivo studies, 177
Ernst, T., see Grob, C.S., 103
Escandon, N.A., see McCall, R.B., 297

Feniuk, W., see Skingle, M., 157
Ferry, R.C. and Molinoff, P.B.
Regulation of 5-HT_{2A} receptor mRNA in P11 cells, 187
Fillion, G., Rousselle, J.-C., Massot, O., Zifa, E., Fillion, M.-P. and Prudhomme, N.
A new peptide, 5-HT-moduline, isolated and purified from mammalian brain specifically interacts with 5-$HT_{1B/1D}$ receptors, 313
Fillion, M.-P., see Fillion, G., 313
Fink, K., see Göthert, M., 89
Finn, J.P., see Liu, Y., 51
Fletcher, A., Forster, E.A., Bill, D.J., Brown, G., Cliffe, I.A., Hartley, J.E., Jones, D.E., McLenachan, A., Stanhope, K.J., Critchley, D.J.P., Childs, K.J., Middlefell, V.C., Lanfumey, L., Corradetti, R., Laporte, A.-M., Gozlan, H., Hamon, M. and Dourish, C.T.
Electrophysiological, biochemical, neurohormonal and

behavioural studies with WAY-100635, a potent, selective and silent 5-HT_{1A} receptor antagonist, 337
Forster, E.A., see Fletcher, A., 337
Fox, J.L., see Johnson, E.A., 331
Frank, R.A., see Moser, P.C., 163
Frölich, D., see Göthert, M., 89
Fujii, A., see Nishio, H., 301
Fuller, R.W.
Serotonin receptors involved in regulation of pituitary-adrenocortical function in rats, 215

Gale, J.D., see Kilpatrick, G.J., 11
Galligan, J.J.
Electrophysiological studies of 5-hydroxytryptamine receptors on enteric neurons, 199
Gershon, M.D., see Kadowaki, M., 293
Geyer, M.A.
Serotonergic functions in arousal and motor activity, 31
Gillette, M.U. and McArthur, A.J.
Circadian actions of melatonin at the suprachiasmatic nucleus, 135
Girardon, S., see Millan, M.J., 69
Gold, P.W., see Burnet, P.W.J., 365
Göthert, M., Fink, K., Frölich, D., Likungu, J., Molderings, G., Schlicker, E. and Zentner, J.
Presynaptic 5-HT auto- and heteroreceptors in the human central and peripheral nervous system, 89
Gozlan, H., see Fletcher, A., 337
Grob, C.S., Poland, R.E., Chang, L. and Ernst, T.
Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations, 103

Hagan, R.M., see Kilpatrick, G.J., 11
Hamon, M., see Fletcher, A., 337
Harris, L.T., see McCall, R.B., 297
Hartley, J.E., see Fletcher, A., 337
Harvey, J.A.
Serotonergic regulation of associative learning, 47
Hayes, W., see Dean, B., 169
Hennig, J., Becker, H. and Netter, P.
5-HT agonist-induced changes in peripheral immune cells in healthy volunteers: The impact of personality, 359
Hen, R., see Ramboz, S., 305
Hill, C., see Dean, B., 169
Hjorth, S. and Auerbach, S.B.
5-HT_{1A} autoreceptors and the mode of action of selective serotonin reuptake inhibitors (SSRI), 281
Honoré, P., see Millan, M.J., 69
Hoyer, D. and Martin, G.R.
Classification and nomenclature of 5-HT receptors: a comment on current issues, 263
Hsu, S., see Wong, E.H.F., 249
Huang, X., see Nichols, D.E., 117
Hurt, S.D., see Palacios, J.M., 239

Jernej, B., see Čičin-Šain, L., 285
Johnson, E.A., Fox, J.L. and Azzaro, A.J.
The anxiolytic serotonin 5-HT_{1A} receptor agonists buspirone, ipsapirone and gepirone are inhibitors of tyrosine hydroxylation in rat striatum, 331
Jones, B.J., see Price, G.W., 79
Jones, D.E., see Fletcher, A., 337

Kadowaki, M., Gershon, M.D. and Kuwahara, A.
Is nitric oxide involved in 5-HT-induced fluid secretion in the gut?, 293
Kao, P.F., see Szabo, Z., 221
Kehne, J.H., see Moser, P.C., 163
Keks, N., see Dean, B., 169
Kellermann, O., see Choi, D-S., 253
Kilbinger, H., see Racké, K., 83
Kilpatrick, G.J.
5-HT_3 and 5-HT_4 receptors in terminal regions of the mesolimbic system, 11
Koob, G.F., see Parsons, L.H., 225
Krantz, D., see Liu, Y., 51
Kuwahara, A., see Kadowaki, M., 293

Lanfumey, L., see Fletcher, A., 337
Laporte, A.-M., see Fletcher, A., 337
Lauder, J.M., see Whitaker-Azmitia, P.M., 19
Launay, J-M., see Choi, D-S., 253
Lee, J., see Weinstein, D., 325
Levy, A.D., see Van de Kar, L.D., 203
Lewy, A.J., Ahmed, S. and Sack, R.L.
Phase-shifting the human circadian clock using melatonin, 131
Likungu, J., see Göthert, M., 89
Li, Q., see Van de Kar, L.D., 203
Liu, Y., Peter, D., Merickel, A., Krantz, D., Finn, J.P. and Edwards, R.H.
A molecular analysis of vesicular amine transport, 51
Lorens, S., see Clancy, Jr., J., 355
Lorens, S.A., see Mathews, H.L., 369
Loric, S., see Choi, D-S., 253
Lucki, I., see Detke, M.J., 43

Magnuson, D., see Weinstein, D., 325
Marona-Lewicka, D., see Nichols, D.E., 117
Maroteaux, L., see Choi, D-S., 253
Martin, G.R., see Hoyer, D., 263
Masana, M.I., see Dubocovich, M.L., 141
Massot, O., see Fillion, G., 313
Mathews, H.L., Lorens, S.A. and Clancy, Jr., J.
Effect of *d*-fenfluramine on the local immune response to the opportunistic microbial pathogen *Candida albicans*, 369
Mathews, W.B., see Szabo, Z., 221
Mazzola-Pomietto, P., see Murphy, D.L., 209
M.B.Tyers, see Skingle, M., 157
McArthur, A.J., see Gillette, M.U., 135
McCall, R.B., Escandon, N.A., Harris, L.T. and Clement, M.E.
Rapid and long duration tolerance to the vagal bradycardic effects of 5-HT_{1A} receptor agonists, 297
McKenna, D.J.
Plant hallucinogens: springboards for psychotherapeutic drug discovery, 109
McLenachan, A., see Fletcher, A., 337
Mefford, I.N., see Burnet, P.W.J., 365
Mengod, G., see Palacios, J.M., 239
Merickel, A., see Liu, Y., 51
Middlefell, V.C., see Fletcher, A., 337
Middlemiss, D.N., see Price, G.W., 79
Millan, M.J., Seguin, L., Honoré, P., Girardon, S. and Bervoets, K.
Pro- and antinociceptive actions of serotonin (5-HT)$_{1A}$ agonists and antagonists in rodents: relationship to algesiometric paradigm, 69
Misslin, R., see Ramboz, S., 305
Molderings, G., see Göthert, M., 89
Molinoff, P.B., see Ferry, R.C., 187
Monsma Jr., F.J., see Sleight, A.J., 245

Monte, A., see Nichols, D.E., 117
Moore, R.Y.
Neural control of the pineal gland, 125
Moran, P.M., see Moser, P.C., 163
Moser, P.C., Moran, P.M., Frank, R.A. and Kehne, J.H.
Reversal of amphetamine-induced behaviours by MDL 100,907, a selective 5-HT_{2A} antagonist, 163
Mulholland, K., see Price, G.W., 79
Mullins, U.L., see Eison, A.S., 177
Murphy, D.L., Aulakh, C., Mazzola-Pomietto, P. and Briggs, N.C.
Neuroendocrine responses to serotonergic agonists as indices of the functional status of central serotonin neurotransmission in humans: A preliminary comparative analysis of neuroendocrine endpoints versus other endpoint measures, 209
Murphy, D.L., see Bonson, K.R., 299
Musachio, J.L., see Szabo, Z., 221
Mylecharane, E.J.
Ventral tegmental area 5-HT receptors: mesolimbic dopamine release and behavioural studies, 1

Nakata, Y., see Nishio, H., 301
Naylor, L., see Dean, B., 169
Netter, P., see Hennig, J., 359
Neuman, R.S. and Rahman, S.
Ca^{2+} mobilizing agents mimic serotonin 5-HT_{2A} facilitation of *N*-methyl-D-aspartate depolarization, 273
Nichols, D.E., Monte, A., Huang, X. and Marona-Lewicka, D.
Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent, 117
Nishio, H., Fujii, A. and Nakata, Y.
Re-examination for pharmacological properties of serotonin-induced tachycardia in isolated guinea-pig atrium, 301

Opeskin, K., see Dean, B., 169

Palacios, J.M., Raurich, A., Mengod, G., Hurt, S.D. and Cortés, R.
Autoradiographic analysis of 5-HT receptor subtypes labeled by [^{3}H]5-CT ([^{3}H]5-carboxamidotryptamine), 239
Pandey, G.N., see Pandey, S.C., 235
Pandey, S.C. and Pandey, G.N.
Modulation of $serotonin_{2A/2C}$ receptors and these receptor-linked phosphoinositide system by ethanol, 235
Parsons, L.H., Koob, G.F. and Weiss, F.
Extracellular serotonin is decreased in the nucleus accumbens during withdrawal from cocaine self-administration, 225
Patel, T.D., Azmitia, E.C. and Zhou, F.C.
Increased 5-HT_{1A} receptor immunoreactivity in the rat hippocampus following 5,7-dihydroxytryptamine lesions in the cingulum bundle and fimbria-fornix, 319
Pavey, G., see Dean, B., 169
Peter, D., see Liu, Y., 51
Poland, R.E., see Grob, C.S., 103
Price, G.W., Roberts, C., Watson, J., Burton, M., Mulholland, K., Middlemiss, D.N. and Jones, B.J.
Species differences in 5-HT autoreceptors, 79
Prudhomme, N., see Fillion, G., 313

Racké, K., Reimann, A., Schwörer, H. and Kilbinger, H.
Regulation of 5-HT release from enterochromaffin cells, 83
Rahman, S., see Neuman, R.S., 273
Ramboz, S., Saudou, F., Amara, D.A., Belzung, C., Segu, L., Misslin, R., Buhot, M-C. and Hen, R.
5-HT_{1B} receptor knock out – behavioral consequences, 305
Raurich, A., see Palacios, J.M., 239
Ravert, H.T., see Szabo, Z., 221
Reid, A., see Sawynok, J., 63
Reimann, A., see Racké, K., 83
Reith, M.E.A., see Cunningham, K.A., 93
Reynolds, G.P., see Wong, E.H.F., 249
Rittenhouse, P.A., see Van de Kar, L.D., 203
Roberts, C., see Price, G.W., 79
Rosay, P., see Choi, D-S., 253
Rousselle, J.-C., see Fillion, G., 313
Routledge, C.
Development of 5-HT_{1A} receptor antagonists, 153

Sack, R.L., see Lewy, A.J., 131
Saudou, F., see Ramboz, S., 305
Sawynok, J. and Reid, A.
Interactions of descending serotonergic systems with other neurotransmitters in the modulation of nociception, 63
Scheffel, U., see Szabo, Z., 221
Schlicker, E., see Göthert, M., 89
Schwörer, H., see Racké, K., 83
Scopes, D.I.C., see Skingle, M., 157
Sebben, M., see Waeber, C., 259
Seguin, L., see Millan, M.J., 69
Segu, L., see Ramboz, S., 305
Shih, J.C., Zhu, Q. and Chen, K.
Determination of transcription initiation sites and promoter activity of the human 5-HT_{2A} receptor gene, 59
Simansky, K.J.
Serotonergic control of the organization of feeding and satiety, 37
Skingle, M., Beattie, D.T., Scopes, D.I.C., Starkey, S.J., Connor, H.E., Feniuk, W. and Tyers, M.B.
GR127935: a potent and selective 5-HT_{1D} receptor antagonist, 157
Sleight, A.J., Monsma Jr., F.J., Borroni, E., Austin, R.H. and Bourson, A.
Effects of altered 5-ht_6 expression in the rat: functional studies using antisense oligonucleotides, 245
Smith, C.C., see Burnet, P.W.J., 365
Stanhope, K.J., see Fletcher, A., 337
Starkey, S.J., see Skingle, M., 157
Sternberg, E.M., see Burnet, P.W.J., 365
Strassman, R.J.
Human psychopharmacology of N,N-dimethyltryptamine, 121
Szabo, Z., Kao, P.F., Mathews, W.B., Ravert, H.T., Musachio, J.L., Scheffel, U. and Dannals, R.F.
Positron emission tomography of 5-HT reuptake sites in the human brain with C-11 McN5652 Extraction of characteristic images by artificial neural network analysis, 221

Toth, M.
Transcriptional regulation of the 5-HT_{2A} receptor, 183
Tricklebank, M.D.
The antipsychotic potential of subtype-selective 5-HT receptor ligands based on interactions with mesolimbic dopamine systems, 15
Tyers, M.B., see Skingle, M., 157

Van de Kar, L.D., Rittenhouse, P.A., Li, Q. and Levy, A.D.
Serotonergic regulation of renin and prolactin secretion, 203

Waeber, C., Sebben, M., Bockaert, J. and Dumuis, A.
Regional distribution and ontogeny of 5-HT_4 binding sites in rat brain, 259
Walker, P., see Whitaker-Azmitia, P.M., 19
Wang, R.Y., Ashby Jr., C.R. and Zhang, J.Y.
Modulation of the A10 dopamine system: electrophysiological studies of the role of 5-HT_3-like receptors, 7
Watson, J., see Price, G.W., 79
Weinstein, D., Magnuson, D. and Lee, J.
Altered G-protein coupling of a frontal cortical low affinity [^{3}H]8-hydroxy-*N,N*-dipropyl-2-aminotetralin serotonergic binding site in Alzheimer's disease, 325
Weiss, F., see Parsons, L.H., 225
Whitaker-Azmitia, P.M., Druse, M., Walker, P. and Lauder, J.M.
Serotonin as a developmental signal, 19
Wong, E.H.F., Reynolds, G.P., Bonhaus, D.W., Hsu, S. and Eglen, R.M.
Characterization of [^{3}H]GR113808 binding to 5-HT_4 receptors in brain tissues from patients with neurodegenerative disorders, 249

Yakel, J.L.
Desensitization of 5-HT_3 receptors expressed in *Xenopus* oocytes: dependence on voltage and primary structure, 269

Zentner, J., see Göthert, M., 89
Zhang, J.Y., see Wang, R.Y., 7
Zhou, F.C., see Patel, T.D., 319
Zhu, Q., see Shih, J.C., 59
Zifa, E., see Fillion, G., 313